Healthcare Market Research

VIDEO: Our Take on ASCO 2018 - Part 2

In this 2nd episode of our post ASCO 2018 miniseries, Gordon Gochenauer shares his takeaways on breast cancer trial results.  Novartis’ CDK4/6 inhibitor, Kisqali, rounds out its clinical portfolio with the MONALEESA-3 trial in a further attempt to unseat Pfizer’s Ibrance and differentiate itself from Eli Lilly’s Verzenio.  Also, AKT inhibitors, ipatasertib from Genentech and capavasertib from AstraZeneca, provide further evidence that PIK3CA/AKT/PTEN-alterations can be another precision medicine target for breast cancer.


Mit dem Laden des Videos akzeptieren Sie die Datenschutzerklärung von YouTube.
Mehr erfahren

Video laden